Sellas Life Sciences Group Inc (SLS : NASDAQ)
Common Stock
$9.68
USD
-1.61 (-14.26%)
Last updated: 2026-09-16
Get SLS alerts:
SLS
Sellas Life Sciences Group Inc
WealthAwesomePerformance
1 Day
+3.28%
1 Week
-16.42%
1 Month
-10.31%
YTD
+50.26%
Key Statistics
Market Cap
$2.35B
52W High
$15.88
52W Low
$1.39
P/E Ratio
-
50 Day MA
$12.62
200 Day MA
$7.14
Beta
2.52
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/16/2026 | $11.24 | $11.73 | $11.24 | $11.66 | $11.66 | 5,088,349 |
| 9/15/2026 | $11.60 | $11.70 | $11.03 | $11.29 | $11.29 | 5,244,009 |
| 9/14/2026 | $10.91 | $12.28 | $10.78 | $11.72 | $11.72 | 10,542,378 |
| 9/11/2026 | $13.55 | $13.74 | $11.38 | $11.54 | $11.54 | 14,709,891 |
| 9/10/2026 | $13.66 | $13.83 | $13.37 | $13.49 | $13.49 | 4,820,200 |
| 9/9/2026 | $13.71 | $14.33 | $13.71 | $13.95 | $13.95 | 5,499,900 |
| 9/8/2026 | $13.77 | $14.37 | $13.32 | $13.96 | $13.96 | 6,055,000 |
| 9/4/2026 | $13.51 | $14.14 | $13.43 | $13.86 | $13.86 | 4,526,900 |
| 9/3/2026 | $14.06 | $14.54 | $13.55 | $13.70 | $13.70 | 5,776,000 |
| 9/2/2026 | $13.27 | $14.33 | $13.23 | $14.16 | $14.16 | 6,236,300 |
Analyst Price Targets
Based on 3 analysts covering SLS · as of Sep 17, 2026
Wall Street analysts forecast SLS stock price to rise 235.7% over the next 12 months.
Consensus
Strong Buy4.67 / 5.00
Avg. Target
US$32.50
+235.7% Upside
Current Price
US$9.68
Last close
Analyst Breakdown (3 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SLS's historical volatility
30-Day Vol
98.6%
Annualized
90-Day Vol
114.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$13.94
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$12.38 | US$8.81 – US$17.39 |
| 60 trading days | US$13.13 | US$8.12 – US$21.24 |
| 90 trading days | US$13.94 | US$7.74 – US$25.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Financials
- Revenue (TTM)
- $0
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- -39.63%
- EPS (Diluted)
- -0.23
- Book Value
- 0.68
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About SLS.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |